<DOC>
	<DOCNO>NCT01088035</DOCNO>
	<brief_summary>This phase II study evaluate feasibility concurrent carboplatin give focal radiation therapy child age 12 month &lt; 21 year newly diagnose localize ependymoma minimal residual disease post-operatively ( &lt; 0.5 cm ) . The hypothesis utilize carboplatin radiosensitizer feasible tolerable may improve event-free survival ( EFS ) minimize local recurrence compare historic control . Following neurosurgical resection staging , patient meet eligibility criterion receive standard fractionate radiation therapy dose 54 59.4 Gy primary site depend upon age . All patient receive 35 mg/m²/day carboplatin prior fraction radiotherapy . Although significant neutropenia anticipate , G-CSF administer per study guideline radiation neutropenia occur . All patient follow toxicity , response ( resolution residual disease ) event-free survival ( EFS ) . Patients ' tumor sample , blood cerebro-spinal fluid ( CSF ) also prospectively evaluated quantify level Survivin , know inhibitor apoptosis , via immunohistochemistry , Western Blot Analysis ( tumor tissue ) ELISA ( blood CSF ) . The feasibility obtain level prospectively real time evaluate .</brief_summary>
	<brief_title>Carboplatin Radiosensitizer Treating Childhood Ependymoma</brief_title>
	<detailed_description />
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must enrol treatment begin . Patients must ≥ 12 month &lt; 22 year age time diagnosis . The target tumor primary brain nonmetastatic ( M0 ) ependymomas tumor . Patients must histologic verification ependymoma diagnosis . Patients follow world health organization ( WHO ) diagnose eligible study : Ependymoma ( Subtypes : cellular , papillary , clear cell tanycytic ) Anaplastic Ependymoma Life expectancy ≥ 8 week . Newly diagnose ependymoma must prior chemotherapy radiotherapy . All patient must : A preoperative MRI scan brain without contrast . NOTE : CT scan NOT sufficient study eligibility since radiation therapy planning response base MRI scan . Postoperative head MRI scan without contrast ( preferably within 72 hour postoperatively ) . Spinal MRI ( T1 weight image without gadolinium ) require within 28 day surgery do postoperatively within 14 day surgery do preoperatively . For posterior fossa tumor , preoperative MRI scan prefer surgically induce inflammation/blood difficult distinguish tumor . Lumbar CSF cytology examination obtain 7 31 day follow surgery . Adequate bone marrow function , define : Peripheral absolute neutrophil count ( ANC ) &gt; 1500/μL Platelet count ≥ 100,000/μL ( transfusion independent ) Hemoglobin ≥ 10.0 gm/dl ( may receive RBC transfusion ) Adequate renal function define : Serum creatinine &lt; 1.5 time upper limit normal base patient 's age , creatinine clearance great 60 ml/min/1.73 m² correct age body surface area . Adequate liver function define : Total bilirubin &lt; 1.5 x institutional normal SGOT ( AST ) SGPT ( ALT ) &lt; 2.5 x institutional normal . Patients must begin chemoradiotherapy within 56 day definitive surgery . All patient and/or parent legal guardian must sign write informed consent Patients must provide assent per local IRB guideline ( applicable ) . Patients and/or family must consent mandatory biology study , include serum Survivin level , CSF Survivin level , paraffinembedded tissue freshfrozen tissue available . Karnofsky/Lansky score great 50 . Corticosteroid supportive care permissible clinician 's discretion prior chemoradiotherapy . Antiseizure medication support permit necessary treat physician 's discretion . Exclusion : Prior chemotherapy prior radiotherapy Patients pregnant breast feeding , patient ( male female ) employ adequate contraception . Acceptable mean birth control include IUD , oral contraceptive , subdermal implant , condom contraceptive sponge suppository abstinence . Patients unable undergo MR imaging Patients evidence metastatic disease spine MRI CSF sample Patients postoperative residual tumor &gt; 0.5 cm , unless repeat surgery perform make residual tumor le 1.5 cm² . Note : Timing enrollment initiation therapy begin second surgery repeat surgery perform .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Childhood ependymoma</keyword>
	<keyword>Ependymoma</keyword>
	<keyword>Survivin</keyword>
</DOC>